Post-earnings recap
Reported
Tue, May 6, 2025
EPS actual
$-3.42
EPS est.
$-0.27
EPS surprise
-1185.71%
1-day move
-26.56%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Sarepta Therapeutics reported a significant loss per share, which was much worse than expected. The stock dropped over 26% in response, reflecting investor disappointment and concerns about the company's financial health. With no revenue reported and no guidance provided, uncertainty looms over the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-3.42 | N/A | -1185.71% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current financial performance and emphasized the importance of their ongoing projects. They did not provide any forward guidance, indicating uncertainty about the near-term outlook.
Management did not provide specific guidance for future quarters.
The company is focusing on ongoing clinical trials and regulatory submissions.